HighVista Strategies’s Immunocore IMCR Stock Holding History

HighVista Strategies’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.77M	Buy	58,697 +25,699	+78%	+$831K	0.49%	62
2025 Q4	$1.15M	Buy	+32,998	New	+$1.16M	0.3%	98
2024 Q2	–	Sell	-34,762	Closed	-$2.26M	–	143
2024 Q1	$2.26M	Sell	34,762 -6,865	-16%	-$471K	0.81%	41
2023 Q4	$2.84M	Buy	41,627 +1,823	+5%	+$94.8K	1.03%	32
2023 Q3	$2.07M	Sell	39,804 -4,290	-10%	-$254K	0.96%	29
2023 Q2	$2.64M	Buy	44,094 +30,900	+234%	+$1.76M	1.21%	23
2023 Q1	$652K	Hold	13,194	–	–	0.53%	64
2022 Q4	$753K	Sell	13,194 -3,394	-20%	-$191K	0.45%	66
2022 Q3	$779K	Buy	+16,588	New	+$791K	0.44%	60

Other funds holding IMCR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

HighVista Strategies's IMCR Position: Q1 2026 in Review

HighVista Strategies increased its Immunocore (IMCR) stake by 78% in Q1 2026, buying an estimated $831K and bringing the position to 58,697 shares worth $1.77M. The position accounts for 0.49% of the portfolio, ranked #62.

HighVista Strategies first reported a position in IMCR in Q3 2022 and has held it in 9 quarters since. The position peaked at $2.84M in Q4 2023. 142 funds tracked by Wall St. Rank hold IMCR as of Q1 2026.

HighVista Strategies held 58,697 shares of Immunocore worth $1.77M as of Q1 2026.
HighVista Strategies bought 25,699 Immunocore shares in Q1 2026, an estimated $831K.
Immunocore made up 0.49% of HighVista Strategies's portfolio in Q1 2026, its #62 holding.
HighVista Strategies first reported a position in Immunocore in Q3 2022 and has held it in 9 quarters since.
HighVista Strategies's Immunocore position peaked at $2.84M in Q4 2023.
142 funds tracked by Wall St. Rank held Immunocore as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.